Bicycle Therapeutics Plc (BCYC) Stock Price, Financials & Summary

Price chart

Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4

Key dataNov 4, 2026

Open$3.75

From 52W high−50.33%

Volume138571.00

Market cap$261.80M

P/E (TTM)—

P/S (TTM)3.1x

Div yield—

Key dataNov 4, 2026

Open

$3.75

From 52W high

−50.33%

Volume

138571.00

Market cap

$261.80M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

1.5x

P/E (TTM)

—

RSI (14)

48.5

MomentumView details →

1D Return

+1.77%

YTD Return

−48.23%

SummaryUpdated Sep 1, 2026

Bicycle Therapeutics plc (NASDAQ:BCYC) is a clinical-stage biopharmaceutical company founded in 2009 and headquartered in Cambridge, United Kingdom. The company went public on NASDAQ in May 2019, raising capital to advance its innovative bicycle peptide drug platform. Bicycle Therapeutics specializes in developing a novel class of medicines called bicycle peptides, which are designed to address diseases that are poorly served by existing therapeutic options, particularly in oncology and other therapeutic areas.

Ask drillr about Bicycle Therapeutics Plc →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

1.5x

EV/Sales

−2.3x

P/S (TTM)

3.1x

P/B (TTM)

0.5x

ProfitabilityView details →

Gross Margin

43.09%

Net Margin

−169.75%

EBITDA Margin

−160.78%

ROE (TTM)

−28.06%

ROA (TTM)

−25.00%

Asset Turnover

0.14x

GrowthView details →

Revenue YoY

+194.75%

EPS YoY

+43.77%

FCF YoY

+28.01%

Revenue CAGR 3Y

+71.21%

EPS CAGR 3Y

−8.59%

EBITDA YoY

+48.49%

MomentumView details →

1D Return

+1.77%

YTD Return

−48.23%

1Y Return

−40.60%

RSI (14)

48.5

vs 50D SMA

−3.35%

vs 200D SMA

−18.93%

Capital & dividendView details →

Debt/Equity

0.03x

Current Ratio

12.09x

Quick Ratio

12.09x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.15

EPS Surprise

62.41%

Beats (12Q)

7/12

Next Q EPS Est

−$0.44

Avg Surprise (4Q)

14.65%

Rev Surprise

178.74%

Financials snapshotView financials →

Revenue (TTM)

83.53M

Net Income (TTM)

−141.79M

Op. CF (TTM)

−174.85M

Next earningsMar 16, 2027 →

Latest newsMore news →

BioUK announced the winners of its 18th annual BioUK Awards across 12 categories.12d ago

Charles Swanton resigned as Class II director of Bicycle Therapeutics PLC's Board of Directors, effective August 18, 2026.77d ago

Similar companies

Q32 Bio Inc.QTTB B&K Corporation Limited02396.HK Amarin Corporation plcAMRN Lexeo Therapeutics, Inc. Common StockLXEO BioAge Labs, Inc.BIOA Quantum-Si incorporatedQSI Find similar companies →

Latest newsMore news →

BioUK announced the winners of its 18th annual BioUK Awards across 12 categories.12d ago Charles Swanton resigned as Class II director of Bicycle Therapeutics PLC's Board of Directors, effective August 18, 2026.77d ago